Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease

作     者：Jose Arriola-Montenegro Renato Beas Renato Cerna-Viacava Andres Chaponan-Lavalle Karla Hernandez Randich Diego Chambergo-Michilot Herson Flores Sanga Pornthira Mutirangura 

作者机构：Department of Internal MedicineUniversity of MinnesotaMinneapolisMN 55455United States Department of MedicineIndiana University School of MedicineIndianaIN 46202United States Department of MedicineHenry Ford HospitalDetroitMI 48202United States Escuela de MedicinaUniversidad Peruana de Ciencias AplicadasLima 15067Peru Universidad Científica del SurLimaPeru Department of TelemedicineCardiologyHospital Nacional Carlos Alberto Seguin EscobedoArequipa 8610Peru Department of MedicineUniversity of MinnesotaMinneapolisMN 55415United States 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2023年第15卷第7期

页      面：328-341页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Non-alcoholic fatty liver disease Heart Failure Heart failure reduced ejection fraction Novel therapies Cardiovascular disease 

摘      要：Heart failure with reduced ejection fraction(HFrEF)and nonalcoholic fatty liver disease(NAFLD)are two common comorbidities that share similar pathophysiological *** is a growing interest in the potential of targeted therapies to improve outcomes in patients with coexisting HFrEF and *** manuscript reviews current and potential therapies for patients with coexisting HFrEF and *** therapies,including angiotensinconverting enzyme inhibitors/angiotensin receptor blockers,mineralocorticoids receptor antagonist,and sodium-glucose cotransporter-2 inhibitors,have been shown to reduce fibrosis and fat deposits in the ***,there are currently no data showing the beneficial effects of sacubitril/valsartan,ivabradine,hydralazine,isosorbide nitrates,digoxin,or beta blockers on NAFLD in patients with *** study highlights the importance of considering HFrEF and NAFLD when developing treatment plans for patients with these *** research is needed in patients with coexisting HFrEF and NAFLD,with an emphasis on novel therapies and the importance of a multidisciplinary approach for managing these complex comorbidities.